BiotechTube

DE-117B Eye Drops + Latanoprost

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Open Angle Glaucoma

Conditions

Open Angle Glaucoma, Ocular Hypertension

Trial Timeline

Nov 28, 2024 → Mar 31, 2026

NCT ID
NCT06666855

About DE-117B Eye Drops + Latanoprost

DE-117B Eye Drops + Latanoprost is a phase 3 stage product being developed by Santen Pharmaceutical for Open Angle Glaucoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06666855. Target conditions include Open Angle Glaucoma, Ocular Hypertension.

What happened to similar drugs?

20 of 20 similar drugs in Open Angle Glaucoma were approved

Approved (20) Terminated (4) Active (0)
✅Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
✅MicafunginAstellas PharmaApproved
✅Teriparatide + Zoledronic AcidEli LillyApproved
✅alendronate sodiumMerckApproved
✅Imipenem + ImipenemMerckApproved
✅Ceftolozane-Tazobactam + MeropenemMerckApproved
✅Ceftolozane-tazobactam IVMerckApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06666855Phase 3Recruiting

Competing Products

20 competing products in Open Angle Glaucoma

See all competitors
ProductCompanyStageHype Score
Ilofotase alfa + PlaceboAM-PharmaPhase 2
25
Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution)Mankind PharmaPhase 3
40
Latanoprost plus adjunctive glaucoma medicationSight SciencesApproved
25
Pirtobrutinib + PlaceboEli LillyPhase 1/2
39
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
17
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, PlaceboSkye BiosciencePhase 2
25
MicafunginAstellas PharmaApproved
39
SDP-133 + LumiganSun PharmaceuticalPhase 3
32
Brinzolamide ophthalmic suspension + Azopt®Sun PharmaceuticalPhase 3
40
Placebo + LusutrombopagShionogiPhase 2
27
LusutrombopagShionogiPhase 2
27
Avatrombopag + Avatrombopag + PlaceboEisaiPhase 2
35
E5501EisaiPhase 1
29
avatrombopagEisaiPhase 1
29
E5501 + Drug: E5501EisaiPhase 1
29
E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with foodEisaiPhase 1
29
Eltrombopag + Avatrombopag + Standard of careEisaiPhase 3
32
Placebo + Avatrombopag tabletsEisaiPhase 2
35
avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count)EisaiPhase 3
40
avatrombopag + PlaceboEisaiPhase 2
35